These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 26871295)
1. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295 [TBL] [Abstract][Full Text] [Related]
2. miR-451a suppresses papillary thyroid cancer cell proliferation and invasion and facilitates apoptosis through targeting DCBLD2 and AKT1. Tan J; Li C; Ren L; Zhu X; Hua F; Fu Y Mol Cell Probes; 2022 Dec; 66():101863. PubMed ID: 36252912 [TBL] [Abstract][Full Text] [Related]
3. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Minna E; Romeo P; De Cecco L; Dugo M; Cassinelli G; Pilotti S; Degl'Innocenti D; Lanzi C; Casalini P; Pierotti MA; Greco A; Borrello MG Oncotarget; 2014 May; 5(9):2513-28. PubMed ID: 24810336 [TBL] [Abstract][Full Text] [Related]
4. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Geraldo MV; Nakaya HI; Kimura ET Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816 [TBL] [Abstract][Full Text] [Related]
5. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Ma Y; Qin H; Cui Y Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698 [TBL] [Abstract][Full Text] [Related]
7. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features. Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472 [TBL] [Abstract][Full Text] [Related]
8. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257 [TBL] [Abstract][Full Text] [Related]
9. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway. Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302 [TBL] [Abstract][Full Text] [Related]
10. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953 [TBL] [Abstract][Full Text] [Related]
11. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma. Li M; Song Q; Li H; Lou Y; Wang L PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287 [TBL] [Abstract][Full Text] [Related]
12. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508 [TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400 [TBL] [Abstract][Full Text] [Related]
14. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway. Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA Profiling in Papillary Thyroid Cancer. Armos R; Bojtor B; Papp M; Illyes I; Lengyel B; Kiss A; Szili B; Tobias B; Balla B; Piko H; Illes A; Putz Z; Kiss A; Toth E; Takacs I; Kosa JP; Lakatos P Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273308 [TBL] [Abstract][Full Text] [Related]
17. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637. Yuan Q; Liu Y; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zhang J; Lu X Int J Biochem Cell Biol; 2018 May; 98():1-9. PubMed ID: 29474928 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871 [TBL] [Abstract][Full Text] [Related]
19. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3. Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577 [TBL] [Abstract][Full Text] [Related]
20. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma. Yang Z; Yuan Z; Fan Y; Deng X; Zheng Q Mol Med Rep; 2013 Nov; 8(5):1353-8. PubMed ID: 24064622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]